Gur, R E
Bassett, A S
McDonald-McGinn, D M
Bearden, C E
Chow, E
Emanuel, B S
Owen, M
Swillen, A
Van den Bree, M
Vermeesch, J
Vorstman, J A S
Warren, S
Lehner, T
Morrow, B
,
Article History
Received: 23 February 2017
Revised: 14 June 2017
Accepted: 19 June 2017
First Online: 1 August 2017
Competing interests
: DMM-M has given lectures on 22q11DS for Natera; CA has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, CIBERSAM, Dainippon Sumitomo Pharma, Fundación Alicia Koplowitz, Forum, Instituto de Salud Carlos III, Gedeon Richter, Janssen Cilag, Lundbeck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Schering Plough, Sunovio and Takeda. DF has been a consultant and/or advisor to or has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Lundbeck, Otsuka and Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía. The other authors declare no conflict of interest.